FzioMed – Pioneering Biomaterials to Improve Patients’ Lives
Pioneering biomaterials since 1996 and having helped more than 1 million patients globally, Fziomed is a recognized global leader in postsurgical adhesion prevention, focused on addressing unmet clinical needs in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures. Fziomed develops, manufactures, and commercializes best-in-class surgical biomaterials used by clinicians to Preserve Surgical Excellence and improve patient outcomes.
Brands: Oxiplex, Dynavisc, Oxiplex/AP, Oxiplex/IU
Fziomed initiated US commercialization of Oxiplex, indicated for reducing postop leg pain and neurological symptoms following lumbar spine procedures.
Company surpassed treating one million patients worldwide over the past 20+ years, including over 800,000 patients undergoing spine procedures.
Level I clinical study results demonstrates that Oxiplex improves pain and neurological outcomes when used as an adjuvant during lumbar spine surgery.
Oxiplex is an intraoperative gel indicated to reduce postop leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures.